Videos
Press Releases
17 Feb 2021
PRESS RELEASE: Generating recommendations for the design, analysis and interpretation of patient- reported outcome (PRO) data for cancer clinical trials: the launch of SISAQOL-IMI
2 Feb 2021
PRESS RELEASE: EORTC 1945 OligoRARE trial in oligometastatic rare cancers receives support by Anticancer Fund & Rising Tide Foundation
20 Jan 2021
PRESS RELEASE: First Patients Tested with InVisionFirst®-Lung in EORTC Sponsored Phase II NSCLC Study
19 Sep 2020
PRESS RELEASE: KEYTRUDA® (pembrolizumab) Reduced the Risk of Distant Metastasis or Death by 40% Compared Versus Placebo as Adjuvant Treatment in Resected, High-Risk Stage III Melanoma
Latest Newsletter
News
5 Nov 2024
EORTC SPRINT clinical cancer study receives support from Rising Tide Foundation to reduce the burden for patients
29 Oct 2024
Pink October at EORTC: Over 60 years of impactful breast cancer research
25 Oct 2024
Do regulations and policies undermine the social value of independent academic research?
10 Oct 2024
EORTC Quality of Life Group’s participation to ISOQOL 2024
8 Oct 2024
New Insights into Glioblastoma Treatment for Older Adults Patients
24 Sep 2024
TOPGEAR trial results show no significant benefit of preoperative chemoradiotherapy on long term survival
17 Sep 2024
Breast Cancer Group,Genito-Urinary Cancers Group,Head and Neck Cancer Group,Lung Cancer Group,Melanoma Group,News
New results and forthcoming EORTC trials in prostate cancer, melanoma, head and neck, lung, rare, and breast cancers presented at ESMO 2024
16 Sep 2024
Late Breaking Results from the EORTC 1333/PEACE III phase III trial
10 Sep 2024
EORTC’s presence at ESMO 2024
